Microradiopharmaceutical for Metastatic Melanoma

Rosa, Thiago Goulart; Santos, Sofia Nascimento dos; Pinto, Terezinha de Jesus Andreoli; Ghisleni, Daniela Dal Molim; Barja-Fidalgo, Thereza Christina; Ricci-Júnior, Eduardo; Al‐Qahtani, Mohammed; Kozempel, Ján; Bernardes, Emerson Soares; Santos-Oliveira, Ralph

doi:10.1007/s11095-017-2275-3

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NPs have been developed for disease diagnosis and targeted drug delivery systems [63,64]. The human tumor cells lines used in this work study are under constant investigation by other groups that have contributed to information about the behavior, mechanisms and treatment efficacy [45,[58][59][60][61][62][63][64][65][66][67][68][69]. Nanomedicine, emerge as a promising platform for theranostic strategies [65].…”

Section: Cell Migration and Tubulogenesismentioning

confidence: 99%

See 1 more Smart Citation

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Helal-Neto

Silva

Saldanha-Gama

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

Nanodrugs have in recent years been a subject of great debate. In 2017 alone, almost 50 nanodrugs were approved for clinical use worldwide. Despite the advantages related to nanodrugs/nanomedicine, there is still a lack of information regarding the biological safety, as the real behavior of these nanodrugs in the body. In order to better understand these aspects, in this study, we evaluated the effect of polylactic acid (PLA) nanoparticles (NPs) and magnetic core mesoporous silica nanoparticles (MMSN), of 1000 nm and 50 nm, respectively, on human cells. In this direction we evaluated the cell cycle, cytochemistry, proliferation and tubulogenesis on tumor cells lines: from melanoma (MV3), breast cancer (MCF-7, MDA-MB-213), glioma (U373MG), prostate (PC3), gastric (AGS) and colon adenocarcinoma (HT-29) and non-tumor cell lines: from human melanocyte (NGM), fibroblast (FGH) and endothelial (HUVEC), respectively. The data showed that an acute exposure to both, polymeric nanoparticles or MMSN, did not show any relevant toxic effects on neither tumor cells nor non-tumor cells, suggesting that although nanodrugs may present unrevealed aspects, under acute exposition to human cells they are harmless.

show abstract

Section: Cell Migration and Tubulogenesismentioning

confidence: 99%

“…Polylactic acid (PLA) polymeric nanoparticles were prepared by double emulsion solvent evaporation technique as described by Rosa et al [58]. Briefly, 2 mL of 1 wt% PVA solution was dripped into 3 mL of dichloromethane, with 100 mg of PLA (with a molar mass of 60,000 g/mol).…”

Section: Polylactic Acid (Pla) Polymeric Nanoparticlesmentioning

confidence: 99%

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Helal-Neto

Silva

Saldanha-Gama

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, Shen et al 35 have used polyoxyethylene sorbitan oleate-modified hollow gold nanoparticles for lung therapy with expressive results. Also, Rosa et al 36 have developed polymeric dacarbazine microparticles radiolabeled with 99m Tc and 223 Ra for lung cancer therapy and diagnosis with good results.…”

Section: Resultsmentioning

confidence: 99%

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

et al. 2022

Self Cite

View full text Add to dashboard Cite

The necessity of new drugs for lung cancer therapy and imaging is increasing each day. The development of new drugs that are capable of reaching the tumor with specificity and selectivity is required. In this direction, the design of nanoparticles for tumor therapy represents an important alternative. The aim of this study was to develop, characterize, and evaluate target-specific atezolizumab-conjugated poly(lactic acid)/poly(vinyl alcohol) (PLA/PVA) nanoparticles as pharmaceutical fragment candidates for new radiopharmaceuticals. For this purpose, PLA/PVA nanoparticle formulations were prepared by the double emulsification/solvent evaporation method with a high-speed homogenizer. A special focus was oriented to the selection of a suitable method for modification of the nanoparticle surface with a monoclonal antibody. For this purpose, atezolizumab was bound to the nanoparticles during the preparation by solvent evaporation or either by adsorption or covalent binding. PLA/PVA/atezolizumab nanoparticles are characterized by dynamic light scattering, Raman spectroscopy, scanning electron microscopy, and atomic force microscopy. An in vitro assay was performed to evaluate the antibody binding efficiency, stability, and cytotoxicity [A549 (lung cancer cell) and L929 (healthy fibroblast cell)]. The results showed that a spherical nanoparticle with a size of 230.6 ± 1.768 nm and a ζ potential of −2.23 ± 0.55 mV was produced. Raman spectroscopy demonstrated that the monoclonal antibody was entrapped in the nanoparticle. The high antibody binding efficiency (80.58%) demonstrated the efficacy of the nanosystem. The cytotoxic assay demonstrated the safety of the nanoparticle in L929 and the effect on A549. In conclusion, PLA/PVA/atezolizumab nanoparticles can be used as drug delivery systems for lung cancer diagnosis and therapy.

show abstract

“…After that, cells were treated with magnetic core-mesoporous silica doped with dacarbazine (0.1-10 mg/ml) in fresh 1% FBS medium DMEM, at 37 C in humidified 5% CO 2 . After 72 h, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed as previously described by Rosa et al [19]. Briefly, cells were incubated with MTT (1 mg/ml) in 1% FBS DMEM, in the dark at 37 C, for 2 h, allowing MTT be reduced to formazan crystals by viable cells.…”

Section: Cytotoxicity Assaymentioning

confidence: 99%

Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography

Portilho

Helal-Neto

Cabezas

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

Cancer is responsible for more than 12% of all causes of death in the world, with an annual death rate of more than 7 million people. In this scenario melanoma is one of the most aggressive ones with serious limitation in early detection and therapy. In this direction we developed, characterized and tested in vivo a new drug delivery system based on magnetic core-mesoporous silica nanoparticle that has been doped with dacarbazine and labelled with technetium 99 m to be used as nano-imaging agent (nanoradiopharmaceutical) for early and differential diagnosis and melanoma by single photon emission computed tomography. The results demonstrated the ability of the magnetic core-mesoporous silica to be efficiently (>98%) doped with dacarbazine and also efficiently labelled with 99mTc (technetium 99 m) (>99%). The in vivo test, using inducted mice with melanoma, demonstrated the EPR effect of the magnetic core-mesoporous silica nanoparticles doped with dacarbazine and labelled with technetium 99 metastable when injected intratumorally and the possibility to be used as systemic injection too. In both cases, magnetic core-mesoporous silica nanoparticles doped with dacarbazine and labelled with technetium 99 metastable showed to be a reliable and efficient nano-imaging agent for melanoma.

show abstract

Microradiopharmaceutical for Metastatic Melanoma

Abstract: The planar image and the possible labeling with Ra-223, corroborates the use as a theragnostic agent for imaging and therapy of Metastatic Melanoma.

Cited by 9 publications

References 27 publications

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography

Contact Info

Product

Resources

About